Skip to main content
. 2021 Dec 21;2(12):100472. doi: 10.1016/j.xcrm.2021.100472

Figure 7.

Figure 7

TP53 mutation and outcome in BCG-treated T1 individuals and alignment of expression subtypes to UROMOL2021 and LundTax classifications

(A) RFS in BCG-treated individuals according to TP53 mutation status.

(B) PFS in BCG-treated individuals according to TP53 mutation status.

(A and B) Log-rank analysis.

(C) Alignment of Ta expression subtypes with UROMOL2021 and LundTax classifications.

(D) Alignment of T1 expression subtypes with UROMOL2021 and LundTax classifications.

(E) Heatmap of Z scores for expression of genes associated with LundTax GU subtype in T1 expression subtypes.

(F) Alignment of T1 CN subtypes with UROMOL2021 and LundTax classifications.